Citation Impact
Citing Papers
A Low-Molecular-Weight Heparinoid Compared with Unfractionated Heparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke
1992
DOUBLE-BLIND RANDOMISED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN PREVENTION OF DEEP-VEIN THROMBOSIS IN THROMBOTIC STROKE
1987
Parenteral Anticoagulants
2008
ORG 10172: a low molecular weight heparinoid anticoagulant with a long half‐life in man.
1987
Parenteral Anticoagulants
2012 Standout
Mechanisms of Thrombus Formation
2008 Standout
Prevention of Deep Vein Thrombosis after Elective Hip Surgery
1991
The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg
1988
Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
2006 Standout
Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis
1994
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
1998 Standout
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Hemostatic and Inflammatory Markers as Risk Factors for Coronary Disease in the Elderly
2002
Low-molecular-weight Heparins for the Treatment of Venous Thromboembolism
1993
Prospects for Cardiovascular Research
2001 StandoutNobel
Childhood obesity: public-health crisis, common sense cure
2002 Standout
Does protamine chloride neutralize low molecular weight heparin sufficiently?
1988
New Antithrombotic Drugs
2012
Platelet-Active Drugs
1998
C-Reactive Protein Levels and Outcomes after Statin Therapy
2005 Standout
Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
1992 Standout
Heparin induces release of extrinsic: Coagulation pathway inhibitor (EPI)
1988
Fibrinolytic Activation Markers Predict Myocardial Infarction in the Elderly
1999
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
2002 Standout
Does atrial fibrillation confer a hypercoagulable state?
1995
Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men
1995 Standout
The biology and pharmacology of PGD2
1988
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism
2004 Standout
Platelet Activation and Atherothrombosis
2007 Standout
Antiplatelet Drugs
2012
Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery
1993
Mutation in blood coagulation factor V associated with resistance to activated protein C
1994 StandoutNature
The end of AIDS: HIV infection as a chronic disease
2013 Standout
C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease
2004 Standout
The effect of molecular weight on heparin binding to platelets
1990
Heparin and Low-Molecular-Weight Heparin
1998
Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
1998
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
1995 Standout
D-dimer determination as a screening tool to exclude atrial thrombi in atrial fibrillation
2003
Atherosclerosis — An Inflammatory Disease
1999 Standout
A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
1995 Standout
Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin
1990
Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
1991 Standout
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
1996
World distribution of factor V Leiden
1995 Standout
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1997 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
Inflammation, Atherosclerosis, and Coronary Artery Disease
2005 Standout
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
2001 Standout
Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men
1997 Standout
Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection
2010
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
2008 Standout
Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.
1989
Acute-Phase Proteins and Other Systemic Responses to Inflammation
1999 Standout
C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women
2000 Standout
Comparative effects of heparin and LMW heparin on hemostasis
1991
Atrial Fibrillation and the Hypercoagulable State: From Basic Science to Clinical Practice
2003
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Effects of Unfractionated Heparin, Dermatan Sulfate and Low Molecular Weight Heparin on Vessel Wall Permeability in Rabbitsa
1989
Management of Venous Thromboembolism
1996
Obesity and the Metabolic Syndrome in Children and Adolescents
2004 Standout
Platelet-Active Drugs
2001
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
2009 Standout
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
2004
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
The Tumor Necrosis Factor Ligand and Receptor Families
1996 StandoutNobel
Low molecular weight heparin in prevention of perioperative thrombosis.
1992
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
2006 Standout
Purification and properties of prostaglandin D synthetase from rat brain.
1979
Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and d -Phe-Pro-Arg-Ch2Cl
1990
Prostaglandin D2, a neuromodulator.
1979
Markers of Inflammation and Cardiovascular Disease
2003 Standout
The Mode of Action of Heparin in Plasma
1988
A glutathione conjugate of hepoxilin A3: formation and action in the rat central nervous system.
1990 StandoutNobel
Low Molecular Weight Heparin Therapy: Is Monitoring Needed?
1994
C-Reactive Protein, Fibrin D-Dimer, and Incident Ischemic Heart Disease in the Speedwell Study
2001
Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides
1984
The relative contributions of antithrombin iii during heparin treatment, and of clinically recognisable risk factors, to early recurrence of venous thromboembolism.
1987
Central Role of Complement in Passive Protection by Human IgG1 and IgG2 Anti-pneumococcal Antibodies in Mice
2003
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis
2009 Standout
The C-type lectin SIGN-R1 mediates uptake of the capsular polysaccharide ofStreptococcus pneumoniaein the marginal zone of mouse spleen
2003 StandoutNobel
Prevention of Deep Vein Thrombosis after Major Knee Surgery - A Randomized, Double-Blind Trial Comparing a Low Molecular Weight Heparin Fragment (Enoxaparin) to Placebo
1992
The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis
1985
Aspirin and Other Platelet-Active Drugs
1992
Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation.
1997
Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.
1994
Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.
1989
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
The Comparative Effects of Recombinant Hirudin (CGP 39393) and Standard Heparin on Thrombus Growth in Rabbits
1990
Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events
2004
Inflammation and Atherosclerosis
2002 Standout
Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma.
1982
The Relationship between Anti-Factor Xa Level and Clinical Outcome in Patients Receiving Enoxaparine Low Molecular Weight Heparin to Prevent Deep Vein Thrombosis after Hip Replacement
1989
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
2002 StandoutScience
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
A Randomized Controlled Trial of a Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip Surgery
1986
Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect
1986
Neutralization of enoxaparine-induced bleeding by protamine sulfate.
1990
Coronary Plaque Disruption
1995 Standout
Prevention of Postoperative Venous Thrombosis: A Randomized Trial Comparing Unfractionated Heparin with Low Molecular Weight Heparin in Patients Undergoing Total Hip Replacement
1988
Low-Molecular-Weight Heparins
1997 Standout
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
1994
Inhibition of low molecular weight heparin by protamine chloride in vivo
1985
The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma
1988
The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin
1987
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
2001 Standout
Fat distribution and hemostatic measures in obese children
1998
Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa
1989
Fibrin D-Dimer and Coronary Heart Disease
2001
Aspirin and other platelet active drugs. Relationship among dose, effectiveness, and side effects.
1989
Prostaglandin D2 is the major prostaglandin of arachidonic acid metabolism in rat bone marrow homogenate
1980
Fibrin d -Dimer and β-Thromboglobulin as Markers of Thrombogenesis and Platelet Activation in Atrial Fibrillation
1996
Antithrombotic Therapy for Venous Thromboembolic Disease
1995
Subcutaneous Low-Molecular-Weight Heparin Compared With Continuous IntravenoUnfractionated Unfractionated Heparin in the Treatment of Proximal Deep Vein Thrombosis
1993
Works of A.L. Cerskus being referenced
The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits
1982
Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography
1980
Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin-iii affinity heparin fraction
1982
Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma
1982
Synthesis of prostaglandin D2 and thromboxane B2 by human platelets
1977
Synthesis of thromboxane B2 and prostaglandins by bovine gastric mucosal microsomes
1977
The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor
1984
Enhanced prothrombin-converting activity and factor Xa binding of platelets activated by the alternative complement pathway
1984
A comparison of the anti thrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation
1984
Activation of factor X and prothrombin in antithrombin-III depleted plasma: The effects of heparin
1981
Possible significance of small numbers of functional platelets in a population of aspirin-treated platelets in vitro and in vivo
1980
Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men.
1994